The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells $232,788.20 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Growth I. L.P. M33 sold 76,324 shares of the stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $3.05, for a total transaction of $232,788.20. Following the transaction, the director now directly owns 1,272,724 shares of the company's stock, valued at $3,881,808.20. This represents a 5.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Oncology Institute Trading Down 6.5%

TOI traded down $0.18 during trading on Monday, hitting $2.60. The company's stock had a trading volume of 1,946,906 shares, compared to its average volume of 998,460. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $3.50. The firm's 50 day moving average price is $2.52 and its 200-day moving average price is $1.27. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The stock has a market cap of $232.01 million, a PE ratio of -3.33 and a beta of 0.13.

Oncology Institute (NASDAQ:TOI - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%. The business had revenue of $104.41 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, BTIG Research began coverage on shares of Oncology Institute in a research note on Thursday, May 15th. They issued a "buy" rating and a $7.00 price objective for the company.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TOI. XTX Topco Ltd boosted its stake in Oncology Institute by 49.5% during the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock valued at $63,000 after acquiring an additional 18,448 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in Oncology Institute in the first quarter valued at about $71,000. WealthShield Partners LLC acquired a new stake in Oncology Institute during the first quarter valued at approximately $80,000. Goldman Sachs Group Inc. bought a new position in Oncology Institute during the 1st quarter worth approximately $131,000. Finally, Jane Street Group LLC lifted its holdings in Oncology Institute by 613.6% during the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after buying an additional 109,769 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company's stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.